List of Posimir drug patents

Posimir is owned by Durect.

Posimir contains Bupivacaine.

Posimir has a total of 4 drug patents out of which 0 drug patents have expired.

Posimir was authorised for market use on 01 February, 2021.

Posimir is available in solution, extended release;infiltration dosage forms.

Posimir can be used as method for providing sustained local anesthesia for at least 24 hours.

The generics of Posimir are possible to be released after 15 September, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8753665 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8846072 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8153661 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8153149 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: Method for providing sustained local anesthesia for at least 24 hours

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

More Information on Dosage

Posimir is owned by Innocoll.

Posimir contains Bupivacaine.

Posimir has a total of 1 drug patent out of which 0 drug patents have expired.

Posimir was authorised for market use on 01 February, 2021.

Posimir is available in solution, extended release;infiltration dosage forms.

The generics of Posimir are possible to be released after 12 January, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400019 INNOCOLL Sustained release drug delivery systems with reduced impurities and related methods
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: NA

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic